European Primary Care Cardiovascular Society
CV health scores have decreased over the past 20 years, resulting in an increased risk of developing subclinical disease and incident CVD, as well as all-cause mortality.
EPCCS 2018 Despite the known efficacy of lipid-lowering therapy, in clinical reality still many patients remain at high risk, for instance due to statin intolerance. The panel discusses how to manage this, and also which risk assessment tools can be used in which patients, to guide treatment decisions.
Healthy food intake was associated with having no coronary artery calcium, and in combination with higher cardiorespiratory fitness, it was also associated with lower CAC levels.
A Google-driven nocebo effect may underlie statin intolerance, as countries with many websites on statin side-effects showed a higher prevalence of statin intolerance.
Moderate and severe malnutrition in HF patients, assessed with simple malnutrition scores, was associated with higher all-cause mortality.
Patients with hypertension with low platelet counts and high total homocysteine levels, which may promote platelet adherence, had the highest risk of first stroke, and this risk was reduced with folic acid treatment.
Electric and magnetic fields generated during operation and charging of electric cars did not affect the function or programming of cardiac implantable electronic devices.
24-hour, daytime, and nighttime ambulatory systolic blood pressure measurements were better predictors of all-cause and CV mortality compared with blood pressure measurements in the clinic.
Based on the new blood pressure definitions for children, the estimated population prevalence of hypertension in individuals aged 5-18 years increased from 11.8% to 14.2%.
Obesity in childhood that persists or worsens during adulthood is associated with higher risks of developing hypertension, T2DM, and dyslipidemia.
Based on objective and critical appraisal of the literature on potential adverse effects of statins, the EAS Consensus Panel concludes that statin treatment is remarkably safe.
A model assuming 100% adherence to maximal statin dose showed that only 10% of heFH patients with CHD would reach guideline-recommended LDL-c goal, and about half of those without CHD.
